ALAlphabet Inc.
Institutional investor · Portfolio as of Q4 2022
Top Holdings51 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
PRIME MEDICINE INC | 13.3M | $246.8M | 14.3% | $18.58 | 0.00% | 1 qtr | New 95 |
VERVE THERAPEUTICS INC | 10.5M | $204.1M | 11.9% | — | — | 1 qtr | New 94 |
UIPATH INC | 14.1M | $178.8M | 10.4% | $12.71 | 0.00% | 1 qtr | New 94 |
DEXCOM INC | 1.3M | $141.6M | 8.2% | $113.24 | 0.00% | 1 qtr | New 93 |
PLANET LABS PBC | 31.9M | $139M | 8.1% | $4.35 | 0.00% | 1 qtr | New 93 |
EQRx Inc. | 47.7M | $117.3M | 6.8% | — | — | 1 qtr | New 93 |
SNOWFLAKE INC-CLASS A | 535,604 | $76.9M | 4.5% | $143.54 | 0.00% | 1 qtr | New 82 |
CROWDSTRIKE HOLDINGS INC - A | 622,073 | $65.5M | 3.8% | $105.29 | 0.00% | 1 qtr | New 82 |
FRESHWORKS INC | 4M | $59.4M | 3.4% | $14.71 | 0.00% | 1 qtr | New 82 |
OSCAR HEALTH INC - CLASS A | 24M | $59.1M | 3.4% | $2.46 | 0.00% | 1 qtr | New 82 |
GITLAB INC | 1.3M | $58.8M | 3.4% | $45.44 | 0.00% | 1 qtr | New 82 |
LYFT INC-A | 5.3M | $57.9M | 3.4% | $11.02 | 0.00% | 1 qtr | New 81 |
DUOLINGO INC | 704,444 | $50.1M | 2.9% | $71.13 | 0.00% | 1 qtr | New 76 |
ROBINHOOD MARKETS INC - A | 4.9M | $40.1M | 2.3% | $8.14 | 0.00% | 1 qtr | New 75 |
Benson Hill Inc. | 15.4M | $39.7M | 2.3% | — | — | 1 qtr | New 75 |
RELAY THERAPEUTICS INC | 1.6M | $23.4M | 1.4% | $14.94 | 0.00% | 1 qtr | New 65 |
LYELL IMMUNOPHARMA INC | 5.9M | $20.4M | 1.2% | — | — | — | — |
Desktop Metal Inc. | 11M | $15M | 0.9% | — | — | — | — |
23andMe Holding Co. | 6.7M | $14.6M | 0.8% | — | — | 1 qtr | New 55 |
BEAM THERAPEUTICS INC | 321,604 | $12.6M | 0.7% | $39.11 | 0.00% | 1 qtr | New 54 |
Alphabet Inc. manages $1.7B across 51 positions as of Q4 2022. Top holdings: PRME (14.3%), VERV (11.9%), PATH (10.4%). Fund DNA: Concentrated Value. HoldingsIntel Rating: 1.5/5.0.
Active quarter - 51 new positions, 0 exits, 0 increased. Top move: PRME (NEW, conviction 95). Portfolio: $1.7B across 51 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
No active accumulation streaks detected for this filer.
Streaks require 2+ consecutive quarters of increased positions in the most recent period.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer